We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Troponin Assays Receive US Marketing Clearance

By LabMedica International staff writers
Posted on 08 Aug 2018
Two high precision assays for the measurement of the cardiac marker troponin I (TnIH) have been certified for marketing in the United States.

The detection of a rise and/or fall of cardiac troponin (cTn) plays a key role in the early diagnosis of myocardial infarction (MI). More...
Cardiac troponins are markers of myocardial necrosis, and, because of their high cardiac-specificity, are the preferred biomarker for the diagnosis of MI.

Troponin is a complex of three contractile regulatory proteins, troponin C, T, and I that control the calcium mediated interactions between actin and myosin in cardiac and skeletal muscles. Troponin I and T are specific to cardiac muscles, unlike troponin C which is associated with both cardiac and skeletal muscles. Both troponin I and troponin T are released into circulation at the time of injury following the same release pattern in the system. However, cardiac troponin I is slightly more differentiated from skeletal troponin I than cardiac troponin T is from skeletal troponin T.

Siemens Healthineers (Erlangen, Germany) has announced that two of its high precision troponin assays have been cleared by the [U.S.] Food and Drug Administration. The High-Sensitivity Troponin I assays (TnIH) for Siemens' Atellica (immunoassay and clinical chemistry analyzer) and ADVIA Centaur XP/XPT (immunoassay system) instruments are now available in the United States.

The high-sensitivity performance of the two new TnIH assays enables detection of lower levels of troponin at significantly improved precision at the 99th percentile, and detects smaller changes in a patient’s troponin level during repeated testing.

The High-Sensitivity Troponin I assays from Siemens Healthineers will be highlighted during the 70th AACC Annual Scientific Meeting & Clinical Lab Expo taking place from July 31 to August 2, 2018, in Chicago, IL, USA.

“Our emergency department is overcrowded with patients. If we can do a more efficient job at triaging patients to receive the proper level of care and to discharge the patients who do not need to stay in the emergency department, this will have a tremendous economic advantage for our healthcare system,” said Dr. Alan Wu, chief of clinical chemistry and toxicology at Zuckerberg San Francisco General Hospital and Trauma Center.


New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Sample Transportation System
Tempus1800 Necto
New
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Microbiology

view channel
Image: New diagnostics could predict a woman’s risk of a common sexually transmitted infection (Photo courtesy of 123RF)

New Markers Could Predict Risk of Severe Chlamydia Infection

Chlamydia trachomatis is a common sexually transmitted infection that can cause pelvic inflammatory disease, infertility, and other reproductive complications when it spreads to the upper genital tract.... Read more

Pathology

view channel
image: Researchers Marco Gustav (right) and MD Nic G. Reitsam (left) discuss the study data (Photo courtesy of Anja Stübner/EKFZ)

AI Model Simultaneously Detects Multiple Genetic Colorectal Cancer Markers in Tissue Samples

Colorectal cancer is a complex disease influenced by multiple genetic alterations. Traditionally, studies and diagnostic tools have focused on predicting only one mutation at a time, overlooking the interplay... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.